Advertisement

October 31, 2016

Cardinal Health Announces Strategic Distribution Agreements in International Markets

October 31, 2016—Cardinal Health announced several new strategic distribution agreements that will enable Cordis, Cardinal Health’s interventional vascular business, to expand its product portfolio in select countries globally. These distribution agreements are related to coronary stents and percutaneous transluminal coronary angioplasty (PTCA) balloon catheters in Cordis’ portfolio of products that support the treatment of patients undergoing percutaneous coronary intervention. The agreements are:

  • An expansion of its current distribution agreement with Biosensors International Group, Ltd. that will enable Cordis to be the exclusive distributor for Biosensors’ coronary interventional products in Japan. Cordis will now distribute Biosensors’ coronary stent portfolio in approximately 27 countries in Europe, the Middle East, and Africa (EMEA), in addition to Japan, Australia, and New Zealand.
  • A distribution agreement with Kaneka Corporation that enables Cordis to distribute Kaneka’s PTCA balloon catheters in EMEA, and select countries in Asia Pacific and Latin America. In Japan, Korea, Australia, and New Zealand, Cordis will sell versions of Kaneka’s PTCA balloon catheters under the names of Neon and Neon NC. In China, Cordis will be the sole distributor of Ikazuchi Rev and Fortis II, under Kaneka’s brand. Upon Kaneka receiving CE Mark approval in Europe and other regulatory clearances in EMEA, China, and select Latin American countries, Cordis will begin to sell the Ikazuchi Zero and Raiden 3 PTCA balloons under the Kaneka brand name.
  • A distribution agreement with Meril Life Sciences Pvt. Ltd. that enables Cordis to sell Meril’s Mozec and Mozec NC Rx PTCA balloon dilatation catheters in the United States and Canada.
  • A strategic agreement with Tryton Medical Inc. Cardinal advised that it is committed to a long-term relationship in the United States where Tryton is currently seeking regulatory approval for their coronary side branch stent. Tryton also announced the agreement on October 28.

Advertisement


October 31, 2016

NOBLE Trial Compares PCI and CABG to Treat Left Main Coronary Artery Disease

October 31, 2016

FANTOM II Results Presented for Reva Medical's Fantom Bioresorbable Vascular Scaffold